Trinity Biotech Plc announced a plan to change its ADS ratio from 1 ADS representing 20 Class A ordinary shares to 1 ADS representing 600 Class A ordinary shares, which has the effect of a 1-for-30 reverse ADS split. The change is intended to regain compliance with the Nasdaq minimum bid price requirement and facilitate investment from a broader pool of potential investors. The effective date is expected to be July 24, 2026. Trinity Biotech is a biotechnology company focused on human diagnostics and diabetes management solutions.
